Wird geladen...
Clinical applications of PD-L1 bioassays for cancer immunotherapy
Programmed death ligand 1 (PD-L1) has emerged as a biomarker that can help to predict responses to immunotherapies targeted against PD-L1 and its receptor (PD-1). Companion tests for evaluating PD-L1 expression as a biomarker of response have been developed for many cancer immunotherapy agents. Thes...
Gespeichert in:
| Veröffentlicht in: | J Hematol Oncol |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BioMed Central
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5436438/ https://ncbi.nlm.nih.gov/pubmed/28514966 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-017-0479-y |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|